title: Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
abstract: BACKGROUND
  This article aims to assess the efficacy and safety of atomoxetine in Korean adults with attention-deficit hyperactivity disorder (ADHD).
  
  
  METHODS
  This post hoc double-blind, placebo-controlled study of atomoxetine (40-120 mg/day) over 10 weeks in adults with ADHD at 45 Japanese, Korean, and Taiwanese study sites focused on patient data from Korea (atomoxetine, n = 37; placebo, n = 37). Primary efficacy outcome was change in baseline-to-endpoint Conners' Adult ADHD Rating Scale-Investigator-rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms score. Secondary efficacy outcomes included changes in Adult ADHD Quality of Life (AAQoL) total, Behavior Rating Inventory of Executive Function-Adult Version Self-Report (BRIEF-A:Self-Report), and Clinical Global Impression-ADHD-Severity (CGI-ADHD-S) scale scores.
  
  
  RESULTS
  Atomoxetine-treated patients demonstrated a mean 18.9-point reduction in CAARS-Inv:SV total ADHD Symptoms score, compared with the 7.45-point reduction in placebo-treated patients (P ≤ 0.01). Significantly greater improvement was found for atomoxetine versus placebo in CGI-ADHD-S (P ≤ 0.01), BRIEF-A:Self-Report global executive composite (P ≤ 0.05), and metacognition index (P ≤ 0.01) executive function scores. Nausea, decreased appetite, and dry mouth were reported with significantly greater frequency by atomoxetine-treated patients, and only one placebo-treated patient discontinued because of adverse event. A 2.1-kg reduction in weight and a 7.5-beat/minute increase in pulse rate were observed in atomoxetine-treated patients.
  
  
  CONCLUSIONS
  These data support a significant benefit of 80- to 120-mg once daily atomoxetine versus placebo for treatment of ADHD in adult Korean patients. A high placebo response rate was observed in this adult Korean sample; a higher discontinuation rate was also observed in atomoxetine-treated patients. These observations warrant further investigation.
authors.affiliation: Department of Psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.
authors.forename: Soyoung Irene
authors.initials: SI
authors.lastname: Lee
authors.forename: Dong-Ho
authors.initials: DH
authors.lastname: Song
authors.forename: Dong Won
authors.initials: DW
authors.lastname: Shin
authors.forename: Ji Hoon
authors.initials: JH
authors.lastname: Kim
authors.forename: Young Sik
authors.initials: YS
authors.lastname: Lee
authors.forename: Jun-Won
authors.initials: JW
authors.lastname: Hwang
authors.forename: Tae Won
authors.initials: TW
authors.lastname: Park
authors.forename: Ki-Hwan
authors.initials: KH
authors.lastname: Yook
authors.forename: Jong Il
authors.initials: JI
authors.lastname: Lee
authors.forename: Geon Ho
authors.initials: GH
authors.lastname: Bahn
authors.forename: Yuko
authors.initials: Y
authors.lastname: Hirata
authors.forename: Taro
authors.initials: T
authors.lastname: Goto
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Takita
authors.forename: Michihiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Sanghoon
authors.initials: S
authors.lastname: Lee
authors.forename: Tamás
authors.initials: T
authors.lastname: Treuer
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011437:Propylamines / Q000008:administration & dosage* / Q000009:adverse effects; D011788:Quality of Life; D056910:Republic of Korea; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride
keywords: ADHD; Korea; atomoxetine; executive function; quality of life